The top pre-market NASDAQ stock market gainers are: dELiA*s, OmniVision Technologies, Ancestry.com, Crocs, and Savient Pharmaceuticals. The top pre-market NASDAQ stock market losers are: NutriSystem, MedAssets, Limelight Networks, First Solar, and Hansen Natural.
Shares of dELiA*s, Inc. (DLIA) climbed 26.88 percent to $2.36 in the pre-market session. The company is up for sale and is also looking at other options including capital raising, the New York Times reported citing people familiar with the matter. The company has prospected interest among potential buyers including private equity firms, the newspaper reported.
OmniVision Technologies Inc. (OVTI) stock jumped 18.66 percent to $28.30 in the pre-market trading, as it guided fourth quarter earnings and revenue above Street view. The company expects fourth quarter adjusted earnings of 57 cents to 70 cents a share and revenue of $240 million to $260 million, while Street predicts profit of 44 cents a share on revenue of $217.18 million.
OmniVision reported third quarter adjusted profit of $50.99 million or 84 cents a share, up from $10.84 million or 20 cents a share last year. Revenue rose to $265.7 million from $156.9 million. Analysts had expected profit of 58 cents a share on revenue of $241.74 million.
Ancestry.com Inc. (ACOM) advanced 8.07 percent to $36.71 in the pre-market session. Profit for the fourth quarter was $12.55 million or $0.25 a share, up from $9.07 million or $0.20 a share last year. Revenue rose 37 percent to $82.74 million. Analysts had expected profit of $0.25 a share on revenue of $81.27 million.
Ancestry.com expects first quarter revenue of $86 million to $88 million, while Street predicts $83.68 million. The company projects full year 2011 revenue of $370 million to $375 million, while Street predicts $357.42 million.
Crocs Inc. (CROX) stock advanced 6.19 percent to $19.21 in the pre-market trading. Profit for the fourth quarter was $4.7 million or $0.05 a share, compared to a loss of $11.4 million or $0.13 a share last year. Revenue rose 32 percent to $179.2 million. Analysts had expected profit of $0.02 a share on revenue of $165.95 million. The company expects first quarter earnings of about $0.19 a share and revenue of about $215 million, while Street predicts profit of $0.17 a share on revenue of $202.80 million.
Crocs said it has named Andrew Davison as chief marketing officer. Davison will be responsible for leading all aspects of Crocs’ marketing including the company’s advertising, consumer promotions and online communications campaigns.
Savient Pharmaceuticals, Inc. (SVNT) stock increased 5.60 percent to $9.99 in the pre-market trading. The company a nnounced the official full U.S. commercial launch of KRYSTEXXA (pegloticase), which has been approved by FDA for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.
Savient's fourth quarter loss widened to $451,000 or 1 cent a share from $219,000 or breakeven a share last year. Revenue rose to $960,000 from $864,000. Analysts had expected a loss of 26 cents a share on revenue of $1.01 million.
Shares of NutriSystem Inc. (NTRI) plunged 26.78 percent to $14.79 in the pre-market trading, as it posted weak fourth quarter revenue and said its results will continue to be hit by competitive pressures through 2011. The disappointing results in January and continued expected competitive challenges have caused the company to forecast 2011 revenues and profitability below 2010 levels.
NutriSystem still expects a profitable year in 2011, with earnings of 40 cents to 50 cents a share and positive adjusted EBITDA. In the first quarter, the company said reduced revenues, margin pressure, and one-time charges, including severance, will result in a forecasted first quarter loss of 30 cents to 35 cents a share. Street analysts predict profit of 30 cents a share for the first quarter and $1.32 a share for fiscal 2011.
NutriSystem posted fourth quarter earnings from continuing operations of $7.08 million or 25 cents a share, up from $5.79 million or 19 cents a share last year. Revenue declined to $87.86 million from $105.45 million. Analysts had expected profit of 25 cents a share on revenue of $100.64 million.
MedAssets, Inc. (MDAS) stock plummeted 24.72 percent to $16.05 in the pre-market session, as it guided fiscal 2011 earnings and revenue below Street view. The company expects fiscal 2011 adjusted cash earnings of $0.94 to $1.04 a share and adjusted acquisition-affected revenue of $588 million to $602 million, while Street predicts profit of $1.14 a share on revenue of $626.20 million.
MedAssets reported fourth quarter loss of $49.4 million or or $0.87 a share, compared to a profit of $10.0 million or $0.17 a share last year. Adjusted cash earnings were $0.18 a share, down from $0.28 a share. Revenue rose to $107.0 million from $95.7 million, while adjusted revenue grew to $120.4 million from $95.7 million. Analysts had expected profit of 22 cents a share on revenue of $122.17 million.
Robert W. Baird downgraded its rating on shares of MedAssets to neutral from outperform and lowered its price target to $18 from $24.
Shares of Limelight Networks, Inc. (LLNW) fell 5.15 percent to $7.37 in the pre-market trading. The company said it and certain stockholders plan to sell its common shares in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies & Company, Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
First Solar, Inc. (FSLR) stock slid 3.15 percent to $159.50 in the pre-market session, as its fourth quarter net sales decreased due to lower systems revenue and module prices. Net sales declined to $610 million from $641 million, while Street predicted $647.80 million.
Shares of Hansen Natural Corp. (HANS) declined 1.54 percent to $53.85 in the pre-market trading. Profit for the fourth quarter was $49.1 million or $0.53 a share, down from $53.4 million or $0.57 a share last year. Sales rose 9.5 percent to $318.7 million. Analysts had expected profit of $0.62 a share on revenue of $329.24 million.